The ability of tolcapone to cross the blood–brain barrier and its potential to bind to TTR within the cerebrospinal fluid make this drug particularly attractive for repurposing efforts aimed at treating ATTRv amyloidosis with leptomeningeal involvement. The gene discussed is TTR; the disease is amyloidosis.